Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

Altri documenti

Y0001437

Nateglinide

European Pharmacopoeia (EP) Reference Standard

Sinonimo/i:

Fastic, N-[(trans-4-isopropylcyclohexyl)carbonyl]-D-phenylalanine, Starlix, Starsis

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C19H27NO3
Numero CAS:
105816-04-4
Peso molecolare:
317.42
Numero MDL:
MFCD00875706
Codice UNSPSC:
41116107
ID PubChem:
329831425
NACRES:
NA.24

Grado

pharmaceutical primary standard

Famiglia di API

nateglinide

Produttore/marchio commerciale

EDQM

applicazioni

pharmaceutical (small molecule)

Formato

neat

Temperatura di conservazione

2-8°C

Stringa SMILE

CC(C)[C@@H]1CC[C@H](CC1)C(=O)N[C@H](Cc2ccccc2)C(O)=O

InChI

1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)/t15-,16-,17-/m1/s1
OELFLUMRDSZNSF-BRWVUGGUSA-N

Informazioni sul gene

human ... ABCC8(6833) , KCNJ11(3767)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Categorie correlate

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Nateglinide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Azioni biochim/fisiol

Nateglinide is a Kir6.2/SUR1 channel inhibitor and antidiabetic. It is selective for the SUR1 subtype, which is found on pancreatic islet cells. Nateglinide evokes KATP channel-dependent insulin secretion (50-200 μM) in the absence and presence of insulin.

Confezionamento

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Altre note

Sales restrictions may apply.

Prodotti correlati

N° Catalogo
Descrizione
Determinazione del prezzo

1457607

Nateglinide, United States Pharmacopeia (USP) Reference Standard

1457618

Nateglinide Related Compound A, United States Pharmacopeia (USP) Reference Standard

1457629

Nateglinide Related Compound B, United States Pharmacopeia (USP) Reference Standard

Y0001440

Nateglinide impurity A, European Pharmacopoeia (EP) Reference Standard

Y0001442

N-[(cis-4-Isopropylcyclohexyl)carbonyl]-D-phenylalanine, European Pharmacopoeia (EP) Reference Standard

Y0001441

Nateglinide impurity B, European Pharmacopoeia (EP) Reference Standard

PHR3058

Nateglinide Related Compound A, pharmaceutical secondary standard, certified reference material

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Ci dispiace, ma al momento non ci sono COA disponibili online per questo prodotto.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

[Effects of nateglinide in impaired glucose tolerance subjects].
Takahisa Hirose
Nihon rinsho. Japanese journal of clinical medicine, 63 Suppl 2, 438-443 (2005-03-23)
I W Campbell
International journal of clinical practice, 59(10), 1218-1228 (2005-09-24)
Therapy for type 2 diabetes mellitus should aim to control not only fasting, but also postprandial glucose levels. Nateglinide, a d-phenylalanine derivative, restores postprandial early phase insulin secretion in a transient and glucose-sensitive manner without affecting basal insulin levels. As
Marc K Israel et al.
Vascular health and risk management, 4(6), 1167-1178 (2008-01-01)
The increasing prevalence of type 2 diabetes provides impetus for both development of new drugs to improve glycemic control and for reconsideration of treatment strategies with existing agents. Combination therapy with complementary drug classes that act on different aspects of
C J Dunn et al.
Drugs, 60(3), 607-615 (2000-10-13)
Nateglinide is a novel D-phenylalanine derivative that inhibits ATP-sensitive K+ channels in pancreatic beta-cells in the presence of glucose and thereby stimulates the prandial release of insulin. Nateglinide reduces fasting and mealtime blood glucose levels in animals, healthy volunteers, and
T Ikenoue et al.
Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 116(3), 171-180 (2000-10-14)
An early defect in Type 2 diabetes is the loss of acute insulin release after food intake, which causes prolonged elevation of postprandial glucose levels. Suppressing postprandial hyperglycemia is considered to be very important for preventing diabetic complications. Sulfonylureas are
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.